| HOME >> BIOLOGY >> TECHNOLOGY |
CLEVELAND, Dec. 4, 2012 /PRNewswire/ -- NineSigma, Inc., of Cleveland, the leading innovation partner to organizations worldwide, announced today they will work with Cincinnati, OH-based AtriCure, Inc. under the new Ohio Third Frontier Open Innovation Incentive (OII) Program. In August, NineSigma was selected by the State of Ohio to help catalyze the growth of middle market companies, with revenues between $10 million and $1 billion, by accelerating their adoption of open innovation. The Ohio Third Frontier OII is aimed at fostering collaborative innovation that will lead to job creation within Ohio and build competitive advantage on the national and global level.
AtriCure, Inc. is a growing medical device company with a strong presence in atrial fibrillation (AF). They are a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems. These systems are designed to create precise lesions, or scars, in heart tissue for the treatment of atrial fibrillation. AF is the most common irregular heartbeat and is characterized by palpitations, dizziness and shortness of breath.
"Atrial fibrillation affects more than 5.5 million people worldwide and carries with it a five-fold increased risk of stroke. We look forward to beginning our work with the team at AtriCure to help them find best-in-class partners and technologies globally that will advance their cardiac surgical solutions and ability to treat this pervasive condition," said Andy Zynga, CEO of NineSigma.
Open innovation involves "looking to the outside" for technologies, solutions, and ideas to accelerate the development of new products and increase speed to market. Through the Open Innovation Incentive, NineSigma will work closely with solution seekers to create custom networks of innovation providers to find viable solutions, filtering responses for their quality and fit
'/>"/>
| SOURCE NineSigma Copyright©2012 PR Newswire. All rights reserved |